PMID- 28497923
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2092-7355 (Print)
IS  - 2092-7363 (Electronic)
IS  - 2092-7355 (Linking)
VI  - 9
IP  - 4
DP  - 2017 Jul
TI  - CCR3 Monoclonal Antibody Inhibits Eosinophilic Inflammation and Mucosal Injury in 
      a Mouse Model of Eosinophilic Gastroenteritis.
PG  - 360-367
LID - 10.4168/aair.2017.9.4.360 [doi]
AB  - PURPOSE: Although the role of eosinophils in eosinophilic gastroenteritis (EGE) 
      is not fully understood, they are believed to be a principal effector cell. 
      Previous studies have demonstrated that eotaxin and its specific receptor, 
      cysteine-cysteine chemokine receptor-3 (CCR3), play a central role in eosinophil 
      trafficking into the gastrointestinal (GI) tract. Thus, we examined the targeting 
      of CCR3 as a potential therapeutic intervention for EGE in a mouse model. 
      METHODS: Eight- to 10-week-old BALB/c mice were intraperitoneally sensitized and 
      intragastrically challenged with ovalbumin (OVA). Different groups of mice were 
      administered either an anti-CCR3 antibody or a control IgG by intraperitoneal 
      injection 1 hour before each OVA challenge. Eosinophilic inflammation in the 
      intestinal mucosa, mucosal injury, and severity of diarrhea were compared between 
      different groups at 1 hour after final OVA challenge. RESULTS: Anti-CCR3 antibody 
      reduced the number of eosinophils in peripheral blood and intestinal mucosa, but 
      not in bone marrow. This reduction was associated with restoration of reduced 
      villous crypt ratio, increased intestinal epithelial cell proliferation, and 
      weight loss induced by OVA challenge. However, Anti-CCR3 antibody had no effect 
      on the level of OVA specific immunoglobulin E (IgE) and the expression of 
      critical chemokines or cytokines in eosinophil trafficking into the GI tract, 
      such as eotaxin-1, interleukin (IL)-5, and IL-13. CONCLUSIONS: Anti-CCR3 antibody 
      significantly reduced the severity of eosinophilic inflammation, mucosal injury, 
      and diarrhea in a mouse model of food allergen-induced GI eosinophilic 
      inflammation. CCR3 may be a novel therapeutic target for treatment of EGE and 
      other GI eosinophil-mediated diseases.
CI  - Copyright (c) 2017 The Korean Academy of Asthma, Allergy and Clinical Immunology . 
      The Korean Academy of Pediatric Allergy and Respiratory Disease
FAU - Song, Dae Jin
AU  - Song DJ
AD  - Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
AD  - Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, 
      Seoul, Korea. djsong506@korea.ac.kr.
FAU - Shim, Mun Hee
AU  - Shim MH
AD  - Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
FAU - Lee, Nahyun
AU  - Lee N
AD  - Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
FAU - Yoo, Young
AU  - Yoo Y
AD  - Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
AD  - Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, 
      Seoul, Korea.
FAU - Choung, Ji Tae
AU  - Choung JT
AD  - Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
AD  - Environmental Health Center for Childhood Asthma, Korea University Anam Hospital, 
      Seoul, Korea.
LA  - eng
PT  - Journal Article
PL  - Korea (South)
TA  - Allergy Asthma Immunol Res
JT  - Allergy, asthma & immunology research
JID - 101518382
PMC - PMC5446951
OTO - NOTNLM
OT  - CCR3
OT  - eosinophilic gastroenteritis
OT  - eosinophils
COIS- There are no financial or other issues that might lead to conflict of interest.
EDAT- 2017/05/13 06:00
MHDA- 2017/05/13 06:01
PMCR- 2017/07/01
CRDT- 2017/05/13 06:00
PHST- 2016/09/11 00:00 [received]
PHST- 2017/01/31 00:00 [revised]
PHST- 2017/01/31 00:00 [accepted]
PHST- 2017/05/13 06:00 [entrez]
PHST- 2017/05/13 06:00 [pubmed]
PHST- 2017/05/13 06:01 [medline]
PHST- 2017/07/01 00:00 [pmc-release]
AID - 9.360 [pii]
AID - 10.4168/aair.2017.9.4.360 [doi]
PST - ppublish
SO  - Allergy Asthma Immunol Res. 2017 Jul;9(4):360-367. doi: 
      10.4168/aair.2017.9.4.360.